Search

Your search keyword '"Garufi Carlo"' showing total 205 results
Start Over Author "Garufi Carlo"
205 results on '"Garufi Carlo"'

1. A diagnostic circulating miRNA signature as orchestrator of cell invasion via TKS4/TKS5/EFHD2 modulation in human gliomas

Author

Díaz Méndez, Ana Belén, Sacconi, Andrea, Tremante, Elisa, Lulli, Valentina, Caprara, Valentina, Rosanò, Laura, Goeman, Frauke, Carosi, Mariantonia, Di Giuliani, Marta, Vari, Giulia, Silvani, Antonio, Pollo, Bianca, Garufi, Carlo, Ramponi, Sara, Simonetti, Giorgia, Ciusani, Emilio, Mandoj, Chiara, Scalera, Stefano, Villani, Veronica, Po, Agnese, Ferretti, Elisabetta, Regazzo, Giulia, and Rizzo, Maria Giulia

Published
2023
Full Text
View/download PDF

3. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial

Author

Ciardiello, Davide, Bielo, Luca Boscolo, Napolitano, Stefania, Martinelli, Erika, Troiani, Teresa, Nicastro, Antonella, Latiano, Tiziana Pia, Parente, Paola, Maiello, Evaristo, Avallone, Antonio, Normanno, Nicola, Pisconti, Salvatore, Nisi, Claudia, Bordonaro, Roberto, Russo, Alessia Erika, Tamburrini, Emiliano, Toma, Ilaria, Lotesoriere, Claudio, Vallarelli, Simona, Zampino, Maria Giulia, Fazio, Nicola, Curigliano, Giuseppe, Ciardiello, Fortunato, Martini, Giulia, Lonardi, Sara, Cremolini, Chiara, Garufi, Carlo, Tagliaferri, Pierosandro, Tortora, Giampaolo, Pietrantonio, Filippo, Febbraro, Antonio, Rosati, Gerardo, Leo, Silvana, Brunetti, Oronzo, Berardi, Rosanna, Cinieri, Saverio, Scartozzi, Mario, Zaniboni, Alberto, Paoletti, Giancarlo, Ciardiello, D., Boscolo Bielo, L., Napolitano, S., Martinelli, E., Troiani, T., Nicastro, A., Latiano, T.P., Parente, P., Maiello, E., Avallone, A., Normanno, N., Pisconti, S., Nisi, C., Bordonaro, R., Russo, A.E., Tamburini, E., Toma, I., Lotesoriere, C., Vallarelli, S., Zampino, M.G., Fazio, N., Curigliano, G., De Vita, F., Ciardiello, F., and Martini, G.

Published
2024
Full Text
View/download PDF

5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Author

Mendez, Guillermo, O'Connor, Juan Manuel, Yanzi Castilla, Alvaro, Cundom, Juan, Kaen, Diego, Wong, Rachel, Ng, Weng, Aghmesheh, Morteza, Peressoni, Mauricio, Andrade, Carlos, Franke, Fabio, Alves, Gustavo, Cruz, Felipe Jose, Vianna, Karina, Monteiro, Maria Marcela, Raphael, Michael, Berry, Scott, Jang, Raymond, Tan, Ann, Asselah, Jamil, Yanez Weber, Patricio, Mahave, Mauricio, Sanchez, Cesar, Salman, Pamela, Bai, Yuxian, Li, Jin, Zhang, Xiaochun, Liu, Tianshu, Lin, Xiaoyan, Qin, Shukui, Yang, Jianwei, Luo, Suxia, Li, Wei, Ying, Jieer, Chen, Xi, Zeng, Shan, Qu, Yanli, Yang, Lin, Zhao, Lin, Chen, Ping, Pan, Hongming, Li, Enxiao, Ye, Feng, Lu, Jianwei, Liang, Xinjun, Zhao, Qun, Yin, Xianli, Li, Junhe, Ling, Yang, Lv, Guoqing, Li, Shouguo, Guerrero, Alvaro, Rubiano, Juan, Gonzalez Fernandez, Manuel, Manneh Kopp, Ray, Guzman Ramirez, Adrian, Corrales, Luis, Gonzalez Herrera, Ileana, Melichar, Bohuslav, Buchler, Tomas, Svoboda, Tomas, Obermannova, Radka, Vrana, David, Cvek, Jakub, Pfeiffer, Per, Baeksgaard, Lene, Yilmaz, Mette, Boige, Valerie, Lopez-Trabada, Daniel, Borg, Christophe, Pannier, Diane, Hiret, Sandrine, Di Fiore, Frederic, Metges, Jean-Philippe, Arnold, Dirk, Martens, Uwe, Lordick, Florian, Stein, Alexander, Castro, Hugo, Lopez, Karla, Ramirez, Julio, Aguilar, Mynor, Chivalan, Marco, Chan, Wendy, Cheng, Ashley, Yeo, Winnie, Arkosy, Peter, Csoszi, Tibor, Hitre, Erika, Horvath, Zsolt, Lowery, Maeve, McDermott, Ray, Morris, Patrick, Hubert, Ayala, Brenner, Baruch, Ben-Aharon, Irit, Shacham-Shmueli, Einat, Man, Sofia, Pelles Avraham, Sharon, Brenner, Ronen, Mishaeli, Moshe, Di Bartolomeo, Maria, Fazio, Nicola, Lonardi, Sara, Garufi, Carlo, Satoh, Taroh, Hara, Hiroki, Iwagami, Shiro, Yasui, Hisateru, Tsuda, Masahiro, Shimoyama, Tatsu, Shoji, Hirokazu, Sugimoto, Naotoshi, Shibata, Nobuhiro, Yamaguchi, Kensei, Amagai, Kenji, Choda, Yasuhiro, Esaki, Taito, Yabusaki, Hiroshi, Oshima, Takashi, Tsuji, Akihito, Kawakami, Hisato, Kawazoe, Akihito, Ishido, Kenji, Kadowaki, Shigenori, Martinez Rodriguez, Jorge, Herrera Martinez, Marytere, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Balancan, Paola, Damianovich, Dragan, Castro Oliden, Victor, Grados, Julio, Torres, Cesar, Wyrwicz, Lucjan, Wysocki, Piotr, Hajac, Lukasz, Zolnierek, Jakub, Karaszewska, Boguslawa, Rha, Sun Young, Lee, Jeeyun, Ryu, Min-Hee, Oh, Do-Youn, Orlova, Rashida, Tjulandin, Sergey, Fadeeva, Natalia, Makarycheva, Yulia, Nosov, Dmitry, Smagina, Maria, Chan, Sze, Jacobs, Conrad, Kraus, Peter, Landers, Gregory, Robertson, Barbara, Ruff, Paul, Schoeman, Elizabeth, Maurel, Jean-Marc, Diez Garcia, Marc, Jimenez Fonseca, Paula, Gallego Plazas, Javier, Rivera Herrero, Fernando, Miranda Poma, Jesus, Layos Romero, Laura, Fritsch, Ralph, Bastian, Sara, Winterhalder, Ralph, Dosso, Sara De, Kossler, Thibaud, Yeh, Kun-Huei, Yen, Chia-Jui, Chen, Yen-Yang, Lin, Johnson, Bilici, Mehmet, Ozguroglu, Mustafa, Cil, Timucin, Oksuzoglu, Berna, Harputluoglu, Hakan, Karaoglu, Aziz, Hacibekiroglu, Ilhan, Erdogan, Bulent, Yalcin, Suayib, Adamchuk, Hryhoriy, Bondarenko, Igor, Kolesnik, Oleksii, Ostapenko, Yuriy, Kryzhanivska, Anna, Leshchenko, Lurii, Ilin, Ievgen, Shparyk, Yaroslav, Trukhin, Dmytro, Voitko, Nataliia, Roy, Rajarshi, Young, Anna-Mary, Medley, Louise, Shiu, Kai-Keen, Celano, Paul, Overton, Lindsay, Raj, Moses, Dunne, Richard, Wainberg, Zev, Dayyani, Farshid, Larson, Timothy, Kochenderfer, Mark, Yañez, Patricio, Rivera, Fernando, Alves, Gustavo Vasconcelos, Garrido, Marcelo, Fernández, Manuel González, Lowery, Maeve A, Çil, Timuçin, Cruz, Felipe Melo, Wainberg, Zev A, Yin, Lina, Bordia, Sonal, Bhagia, Pooja, and Wyrwicz, Lucjan S

Published
2023
Full Text
View/download PDF

6. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab

Author

Zeuli Massimo, Diodoro Maria, Conti Salvatore, Melucci Elisa, Sperduti Isabella, Merola Roberta, Torsello Angela, Cianciulli Anna, Mottolese Marcella, Campanella Carla, Paoletti Giancarlo, Cognetti Francesco, and Garufi Carlo

Subjects
Medicine
Abstract

Abstract Background Responsiveness to Cetuximab alone can be mediated by an increase of Epidermal Growth factor Receptor (EGFR) Gene Copy Number (GCN). Aim of this study was to assess the role of EGFR-GCN in advanced colorectal cancer (CRC) patients receiving chemotherapy plus Cetuximab. Methods One hundred and one advanced CRC patients (43 untreated- and 58 pre-treated) were retrospectively studied by fluorescence in situ hybridization (FISH) to assess EGFR-GCN and by immunohistochemistry (IHC) to determine EGFR expression. Sixty-one out of 101 patients were evaluated also for k-ras status by direct sequencing. Clinical end-points were response rate (RR), progression-free survival (PFS) and overall survival (OS). Results Increased EGFR-GCN was found in 60/101 (59%) tumor samples. There was no correlation between intensity of EGFR-IHC and EGFR-GCN (p = 0.43). Patients receiving chemotherapy plus Cetuximab as first line treatment had a RR of 70% (30/43) while it was 18% (10/56) in the group with previous lines of therapy (p < 0.0001). RR was observed in 29/60 (48%) of patients with increased EGFR-GCN and in 6/28 (21%) in those without (p = 0.02). At multivariate analyses, number of chemotherapy lines and increased EGFR-GCN were predictive of response; EGFR-IHC score, increased EGFR-GCN and number of chemotherapy lines were significantly associated with a significant better PFS. Response to therapy was the only prognostic predictive factor for OS. In the 60 patients analyzed for k-ras mutations, number of chemotherapy lines, increased EGFR-GCN and k-ras wild type status predicted a better PFS. Conclusion In metastatic CRC patients treated with chemotherapy plus Cetuximab number of chemotherapy lines and increased EGFR-GCN were significantly associated with a better clinical outcome, independent of k-ras status.

Published
2010
Full Text
View/download PDF

7. An integrated psychological strategy for advanced colorectal cancer patients

Author

Giannarelli Diana, Garufi Carlo, Nisi Enrica, Perrone Maria, Pugliese Patrizia, Bottomley Andrew, and Terzoli Edmondo

Subjects
Computer applications to medicine. Medical informatics, R858-859.7
Abstract

Abstract Background There is evidence regarding the usefulness of psychosocial intervention to improve health related quality of life (HRQOL) in adult cancer patients. The aim of this report is to describe an integrated approach and to evaluate its feasibility in routine clinical practice in 98 advanced colorectal cancer (ACC) patients during chronomodulated chemotherapy. Methods A prospective non-randomised design was developed and applied in a cancer out-patient setting. The intervention consisted of an integrated approach, whereby the psycho-oncologist had an active role in the health care team with the physician and routinely included psychological understanding in the medical treatment program. The psychological evaluation assessed: a) adaptation, awareness, psychopathological disorders through a psychodynamic interview; b) anxiety and depression using the HAD scale; c) subjective perception of care quality through a structured interview and d) HRQOL evaluation assessment with the EORTC QLQ C30. Outcomes data were collected before and after 18 weeks of chemotherapy. Results After 18 weeks of chemotherapy a significant improvement of adaptation and awareness was observed. The HADs results showed a significant decrease in anxiety when compared to pre-treatment. The structured interview showed a significant increase of patients who positively experienced the impact of medical treatment on HRQOL, anxiety, depression, interpersonal relationships, free-time and who positively experienced the care quality. Indeed, a majority of patients positively experienced the team relationship modality during the whole treatment. All scales on the EORTC questionnaire remained unchanged during the entire treatment. Conclusion Our results suggest that it is feasible to carry out an integrated approach during chemotherapy. These results seem to support the integrated approach as a tool in aiding advanced colorectal cancer patients' ability to cope with their diagnosis and treatment although an appropriately designed study is required to confirm this.

Published
2006
Full Text
View/download PDF

8. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer

Author

Alfieri, Sergio, Amato, Arnaldo, Amisano, Marco, Anderloni, Andrea, Maestri, Antonio, Coluccio, Chiara, Brandi, Giovanni, Casadei-Gardini, Andrea, Cennamo, Vincenzo, Crinò, Stefano Francesco, Valle, Raffaele Dalla, De Angelis, Claudio, Di Battista, Monica, Di Maio, Massimo, Di Marco, Mariacristina, Di Marco, Marco, Di Matteo, Francesco, Di Mitri, Roberto, Ettorre, Giuseppe Maria, Facciorusso, Antonio, Farina, Gabriella, Ferrari, Giovanni, Fornaro, Lorenzo, Frigerio, Isabella, Frisone, Daniele, Fuccio, Lorenzo, Gardini, Andrea, Garufi, Carlo, Giampieri, Riccardo, Grazi, Gian Luca, Jovine, Elio, Kauffmann, Emanuele, Langella, Serena, Larghi, Alberto, Manno, Mauro, Marciano, Emanuele, Marzioni, Marco, Merighi, Alberto, Mutignani, Massimiliano, Nardo, Bruno, Niger, Monica, Palmisano, Valentina, Partelli, Stefano, Pinto, Carmine, Piras, Enrico, Rapposelli, Ilario Giovanni, Reni, Michele, Ricci, Claudio, Rimassa, Lorenza, Siena, Salvatore, Spada, Cristiano, Sperti, Elisa, Spezzaferro, Mariangela, Sposito, Carlo, Tamberi, Stefano, Troisi, Roberto, Veneroni, Luigi, Vivarelli, Marco, Zerbi, Alessandro, Cucchetti, Alessandro, Djulbegovic, Benjamin, Crippa, Stefano, Hozo, Iztok, Sbrancia, Monica, Tsalatsanis, Athanasios, Binda, Cecilia, Fabbri, Carlo, Salvia, Roberto, Falconi, Massimo, and Ercolani, Giorgio

Published
2023
Full Text
View/download PDF

9. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Author

Reni, Michele, Macchini, Marina, Orsi, Giulia, Peretti, Umberto, Valente, Mariamaddalena, Giommoni, Elisa, Antonuzzo, Lorenzo, Di Costanzo, Francesco, Bergamo, Francesca, Zagonel, Vittorina, Lonardi, Sara, Buggin, Federica, Milella, Michele, Palmerio, Silvia, Cavanna, Luigi, Di Nunzio, Camilla, Di Marco, Maria Cristina, Grassi, Elisa, Spada, Massimiliano, Messina, Marco, Cordio, Stefano, Avola, Francesco, Aprile, Giuseppe, Pagano, Salvatore, Simionato, Francesca, Cardellino, Giovanni Gerardo, Majer, Federica, Maiello, Evaristo, Latiano, Tiziana Pia, Chiarazzo, Cinzia, Artioli, Fabrizio, Razzini, Giorgia, Pasqualini, Antonella, Ghidini, Michele, Binda, Elisa, Lazzarelli, Silvia, Bozzarelli, Silvia, Sala, Simona, Luppi, Gabriele, Pettorelli, Elisa, Spallanzani, Andrea, Vicario, Giovanni, Salmaso, Flavia, Basso, Marco, Silvestris, Nicola, Del Curatolo, Sabina, Zustovich, Fable, Bongiovanni, Francesca, Longobardi, Ciro, Sandi, Ilenia, Fontanella, Caterina, Montelatici, Silvia, Giordano, Monica, Luchena, Giovanna, Gilardoni, Micol, Tamburini, Emiliano, Rudnas, Britt, Venturini, Barbara, Merelli, Barbara, Negrini, Giorgia, Vici, Elio Maria, Marabese, Alessandra, Garetto, Cristina, Curcio, Paola, Cinieri, Saverio, Cinefra, Margherita, Ferrara, Pasqualinda, Cantore, Maurizio, Morselli, Patrizia, Fumi, Guglielmo, Isidori, Agnese, Ciccarese, Giovanni, Paolo Frassineti, Giovanni Luca, Pagan, Flavia, Vaccaro, Vanja, Spoto, Chiara, Ferrara, Marianna, Garufi, Carlo, Caporale, Marta, Vasile, Enrico, Salani, Francesca, Barone, Elisa, Berardi, Rossana, Onofri, Azzurra, Ballatore, Zelmira, Lucarelli, Alessandra, Barucca, Alessandra, Pancotti, Amedeo, Scipioni, Teresa, Bencardino, Katia, Marrapese, Giovanna, Idotta, Laura, Petrelli, Fausto, Lonati, Veronica, Ceribelli, Anna, Giuli, Angelo, Zannori, Cristina, Bassanelli, Maria, Mambrini, Andrea, Ginocchi, Laura, Orlandi, Massimo, Celio, Luigi, Niger, Monica, Biamonte, Lavinia, Tamberi, Stefano, Piancastelli, Alessandra, Papiani, Giorgio, Valli, Irene, Allione, Paolo, Boe, Maria Giovanna, Scartozzi, Mario, Lai, Eleonora, Pireddu, Annagrazia, Ziranu, Pina, Demurtas, Laura, Puzzoni, Marco, Mariani, Stefano, Pretta, Andrea, Liscia, Nicole, Savastano, Clementina, Malaspina, Valentina, Tonini, Giuseppe, Grassani, Teresa, Barco, Barbara, Pierosandro, Tagliaferri, Ciliberto, Domenico, Ierardi, Antonella, Calandruccio, Natale Daniele, Minotti, Vincenzo, Matocci, Roberta, Torri, Valter, Porcu, Luca, Rulli, Erica, De Simone, Irene, Carlucci, Luciano, Rulli, Eliana, Poli, Davide, Tonto, Paola, Scellato, Francesca, Pinto, Carmine, Reni, M., Giommoni, E., Bergamo, F., Milella, M., Cavanna, L., Di Marco, M.C., Spada, M., Cordio, S., Aprile, G., Cardellino, G.G., Maiello, E., Bernardini, I., Ghidini, M., Bozzarelli, S., Macchini, M., Orsi, G., De Simone, I., Rulli, Er., Porcu, L., Torri, V., and Pinto, C.

Published
2023
Full Text
View/download PDF

11. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Author

Rha, Sun Young, primary, Oh, Do-Youn, additional, Yañez, Patricio, additional, Bai, Yuxian, additional, Ryu, Min-Hee, additional, Lee, Jeeyun, additional, Rivera, Fernando, additional, Alves, Gustavo Vasconcelos, additional, Garrido, Marcelo, additional, Shiu, Kai-Keen, additional, Fernández, Manuel González, additional, Li, Jin, additional, Lowery, Maeve A, additional, Çil, Timuçin, additional, Cruz, Felipe Melo, additional, Qin, Shukui, additional, Luo, Suxia, additional, Pan, Hongming, additional, Wainberg, Zev A, additional, Yin, Lina, additional, Bordia, Sonal, additional, Bhagia, Pooja, additional, Wyrwicz, Lucjan S, additional, Mendez, Guillermo, additional, O'Connor, Juan Manuel, additional, Yanzi Castilla, Alvaro, additional, Cundom, Juan, additional, Kaen, Diego, additional, Wong, Rachel, additional, Ng, Weng, additional, Aghmesheh, Morteza, additional, Peressoni, Mauricio, additional, Andrade, Carlos, additional, Franke, Fabio, additional, Alves, Gustavo, additional, Cruz, Felipe Jose, additional, Vianna, Karina, additional, Monteiro, Maria Marcela, additional, Raphael, Michael, additional, Berry, Scott, additional, Jang, Raymond, additional, Tan, Ann, additional, Asselah, Jamil, additional, Yanez Weber, Patricio, additional, Mahave, Mauricio, additional, Sanchez, Cesar, additional, Salman, Pamela, additional, Zhang, Xiaochun, additional, Liu, Tianshu, additional, Lin, Xiaoyan, additional, Yang, Jianwei, additional, Li, Wei, additional, Ying, Jieer, additional, Chen, Xi, additional, Zeng, Shan, additional, Qu, Yanli, additional, Yang, Lin, additional, Zhao, Lin, additional, Chen, Ping, additional, Li, Enxiao, additional, Ye, Feng, additional, Lu, Jianwei, additional, Liang, Xinjun, additional, Zhao, Qun, additional, Yin, Xianli, additional, Li, Junhe, additional, Ling, Yang, additional, Lv, Guoqing, additional, Li, Shouguo, additional, Guerrero, Alvaro, additional, Rubiano, Juan, additional, Gonzalez Fernandez, Manuel, additional, Manneh Kopp, Ray, additional, Guzman Ramirez, Adrian, additional, Corrales, Luis, additional, Gonzalez Herrera, Ileana, additional, Melichar, Bohuslav, additional, Buchler, Tomas, additional, Svoboda, Tomas, additional, Obermannova, Radka, additional, Vrana, David, additional, Cvek, Jakub, additional, Pfeiffer, Per, additional, Baeksgaard, Lene, additional, Yilmaz, Mette, additional, Boige, Valerie, additional, Lopez-Trabada, Daniel, additional, Borg, Christophe, additional, Pannier, Diane, additional, Hiret, Sandrine, additional, Di Fiore, Frederic, additional, Metges, Jean-Philippe, additional, Arnold, Dirk, additional, Martens, Uwe, additional, Lordick, Florian, additional, Stein, Alexander, additional, Castro, Hugo, additional, Lopez, Karla, additional, Ramirez, Julio, additional, Aguilar, Mynor, additional, Chivalan, Marco, additional, Chan, Wendy, additional, Cheng, Ashley, additional, Yeo, Winnie, additional, Arkosy, Peter, additional, Csoszi, Tibor, additional, Hitre, Erika, additional, Horvath, Zsolt, additional, Lowery, Maeve, additional, McDermott, Ray, additional, Morris, Patrick, additional, Hubert, Ayala, additional, Brenner, Baruch, additional, Ben-Aharon, Irit, additional, Shacham-Shmueli, Einat, additional, Man, Sofia, additional, Pelles Avraham, Sharon, additional, Brenner, Ronen, additional, Mishaeli, Moshe, additional, Di Bartolomeo, Maria, additional, Fazio, Nicola, additional, Lonardi, Sara, additional, Garufi, Carlo, additional, Satoh, Taroh, additional, Hara, Hiroki, additional, Iwagami, Shiro, additional, Yasui, Hisateru, additional, Tsuda, Masahiro, additional, Shimoyama, Tatsu, additional, Shoji, Hirokazu, additional, Sugimoto, Naotoshi, additional, Shibata, Nobuhiro, additional, Yamaguchi, Kensei, additional, Amagai, Kenji, additional, Choda, Yasuhiro, additional, Esaki, Taito, additional, Yabusaki, Hiroshi, additional, Oshima, Takashi, additional, Tsuji, Akihito, additional, Kawakami, Hisato, additional, Kawazoe, Akihito, additional, Ishido, Kenji, additional, Kadowaki, Shigenori, additional, Martinez Rodriguez, Jorge, additional, Herrera Martinez, Marytere, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Balancan, Paola, additional, Damianovich, Dragan, additional, Castro Oliden, Victor, additional, Grados, Julio, additional, Torres, Cesar, additional, Wyrwicz, Lucjan, additional, Wysocki, Piotr, additional, Hajac, Lukasz, additional, Zolnierek, Jakub, additional, Karaszewska, Boguslawa, additional, Rha, Sun Young, additional, Orlova, Rashida, additional, Tjulandin, Sergey, additional, Fadeeva, Natalia, additional, Makarycheva, Yulia, additional, Nosov, Dmitry, additional, Smagina, Maria, additional, Chan, Sze, additional, Jacobs, Conrad, additional, Kraus, Peter, additional, Landers, Gregory, additional, Robertson, Barbara, additional, Ruff, Paul, additional, Schoeman, Elizabeth, additional, Maurel, Jean-Marc, additional, Diez Garcia, Marc, additional, Jimenez Fonseca, Paula, additional, Gallego Plazas, Javier, additional, Rivera Herrero, Fernando, additional, Miranda Poma, Jesus, additional, Layos Romero, Laura, additional, Fritsch, Ralph, additional, Bastian, Sara, additional, Winterhalder, Ralph, additional, Dosso, Sara De, additional, Kossler, Thibaud, additional, Yeh, Kun-Huei, additional, Yen, Chia-Jui, additional, Chen, Yen-Yang, additional, Lin, Johnson, additional, Bilici, Mehmet, additional, Ozguroglu, Mustafa, additional, Cil, Timucin, additional, Oksuzoglu, Berna, additional, Harputluoglu, Hakan, additional, Karaoglu, Aziz, additional, Hacibekiroglu, Ilhan, additional, Erdogan, Bulent, additional, Yalcin, Suayib, additional, Adamchuk, Hryhoriy, additional, Bondarenko, Igor, additional, Kolesnik, Oleksii, additional, Ostapenko, Yuriy, additional, Kryzhanivska, Anna, additional, Leshchenko, Lurii, additional, Ilin, Ievgen, additional, Shparyk, Yaroslav, additional, Trukhin, Dmytro, additional, Voitko, Nataliia, additional, Roy, Rajarshi, additional, Young, Anna-Mary, additional, Medley, Louise, additional, Celano, Paul, additional, Overton, Lindsay, additional, Raj, Moses, additional, Dunne, Richard, additional, Wainberg, Zev, additional, Dayyani, Farshid, additional, Larson, Timothy, additional, and Kochenderfer, Mark, additional

Published
2023
Full Text
View/download PDF

12. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

Author

Pizzuti, Laura, Barba, Maddalena, Mazzotta, Marco, Krasniqi, Eriseld, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, La Verde, Nicla, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Sergi, Domenico, Marinelli, Daniele, Paoletti, Giancarlo, Tomao, Silverio, Botticelli, Andrea, Marchetti, Paolo, Tinari, Nicola, Grassadonia, Antonino, Valerio, Maria Rosaria, Mirabelli, Rosanna, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Meattini, Icro, Pistelli, Mirco, Giotta, Francesco, Lorusso, Vito, Garufi, Carlo, Russo, Antonio, Cazzaniga, Marina, Del Medico, Pietro, Roselli, Mario, Vaccaro, Angela, Perracchio, Letizia, di Benedetto, Anna, Daralioti, Theodora, Sperduti, Isabella, De Maria, Ruggero, Di Leo, Angelo, Sanguineti, Giuseppe, Ciliberto, Gennaro, and Vici, Patrizia

Published
2021
Full Text
View/download PDF

13. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Author

Cortellini, Alessio, Chiari, Rita, Ricciuti, Biagio, Metro, Giulio, Perrone, Fabiana, Tiseo, Marcello, Bersanelli, Melissa, Bordi, Paola, Santini, Daniele, Giusti, Raffaele, Grassadonia, Antonino, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Malorgio, Francesco, Garufi, Carlo, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Iacono, Daniela, Migliorino, Maria Rita, Porzio, Giampiero, Cannita, Katia, Ficorella, Corrado, and Buti, Sebastiano

Published
2019
Full Text
View/download PDF

14. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Author

Bon, Giulia, Pizzuti, Laura, Laquintana, Valentina, Loria, Rossella, Porru, Manuela, Marchiò, Caterina, Krasniqi, Eriseld, Barba, Maddalena, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, La Verde, Nicla, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Barchiesi, Giacomo, Mazzotta, Marco, Marinelli, Daniele, Tomao, Silverio, Marchetti, Paolo, Valerio, Maria Rosaria, Mirabelli, Rosanna, Russo, Antonio, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Giotta, Francesco, Garufi, Carlo, Cazzaniga, Marina, Del Medico, Pietro, Roselli, Mario, Sanguineti, Giuseppe, Sperduti, Isabella, Sapino, Anna, De Maria, Ruggero, Leonetti, Carlo, Di Leo, Angelo, Ciliberto, Gennaro, Falcioni, Rita, and Vici, Patrizia

Published
2020
Full Text
View/download PDF

15. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer

Author

Cucchetti, Alessandro, primary, Djulbegovic, Benjamin, additional, Crippa, Stefano, additional, Hozo, Iztok, additional, Sbrancia, Monica, additional, Tsalatsanis, Athanasios, additional, Binda, Cecilia, additional, Fabbri, Carlo, additional, Salvia, Roberto, additional, Falconi, Massimo, additional, Ercolani, Giorgio, additional, Alfieri, Sergio, additional, Amato, Arnaldo, additional, Amisano, Marco, additional, Anderloni, Andrea, additional, Maestri, Antonio, additional, Coluccio, Chiara, additional, Brandi, Giovanni, additional, Casadei-Gardini, Andrea, additional, Cennamo, Vincenzo, additional, Crinò, Stefano Francesco, additional, Valle, Raffaele Dalla, additional, De Angelis, Claudio, additional, Di Battista, Monica, additional, Di Maio, Massimo, additional, Di Marco, Mariacristina, additional, Di Marco, Marco, additional, Di Matteo, Francesco, additional, Di Mitri, Roberto, additional, Ettorre, Giuseppe Maria, additional, Facciorusso, Antonio, additional, Farina, Gabriella, additional, Ferrari, Giovanni, additional, Fornaro, Lorenzo, additional, Frigerio, Isabella, additional, Frisone, Daniele, additional, Fuccio, Lorenzo, additional, Gardini, Andrea, additional, Garufi, Carlo, additional, Giampieri, Riccardo, additional, Grazi, Gian Luca, additional, Jovine, Elio, additional, Kauffmann, Emanuele, additional, Langella, Serena, additional, Larghi, Alberto, additional, Manno, Mauro, additional, Marciano, Emanuele, additional, Marzioni, Marco, additional, Merighi, Alberto, additional, Mutignani, Massimiliano, additional, Nardo, Bruno, additional, Niger, Monica, additional, Palmisano, Valentina, additional, Partelli, Stefano, additional, Pinto, Carmine, additional, Piras, Enrico, additional, Rapposelli, Ilario Giovanni, additional, Reni, Michele, additional, Ricci, Claudio, additional, Rimassa, Lorenza, additional, Siena, Salvatore, additional, Spada, Cristiano, additional, Sperti, Elisa, additional, Spezzaferro, Mariangela, additional, Sposito, Carlo, additional, Tamberi, Stefano, additional, Troisi, Roberto, additional, Veneroni, Luigi, additional, Vivarelli, Marco, additional, and Zerbi, Alessandro, additional

Published
2023
Full Text
View/download PDF

16. A 15-year experience of two hundred and twenty five consecutive right hepatectomies

Author

Levi Sandri, Giovanni Battista, Colasanti, Marco, Vennarecci, Giovanni, Santoro, Roberto, Lepiane, Pasquale, Mascianà, Gianluca, de Werra, Edoardo, Meniconi, Roberto Luca, Campanelli, Alessandra, Scotti, Andrea, Burocchi, Mirco, Di Castro, Angelo, D’Offizi, Giampiero, Antonini, Mario, Busi Rizzi, Elisa, Ialongo, Pasquale, Garufi, Carlo, and Ettorre, Giuseppe Maria

Published
2017
Full Text
View/download PDF

17. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

Author

Valtorta, Emanuele, Martino, Cosimo, Sartore-Bianchi, Andrea, Penaullt-Llorca, Frédérique, Viale, Giuseppe, Risio, Mauro, Rugge, Massimo, Grigioni, Walter, Bencardino, Katia, Lonardi, Sara, Zagonel, Vittorina, Leone, Francesco, Noe, Johannes, Ciardiello, Fortunato, Pinto, Carmine, Labianca, Roberto, Mosconi, Stefania, Graiff, Claudio, Aprile, Giuseppe, Frau, Barbara, Garufi, Carlo, Loupakis, Fotios, Racca, Patrizia, Tonini, Giuseppe, Lauricella, Calogero, Veronese, Silvio, Truini, Mauro, Siena, Salvatore, Marsoni, Silvia, and Gambacorta, Marcello

Published
2015
Full Text
View/download PDF

18. Additional file 1 of A diagnostic circulating miRNA signature as orchestrator of cell invasion via TKS4/TKS5/EFHD2 modulation in human gliomas

Author

Díaz Méndez, Ana Belén, Sacconi, Andrea, Tremante, Elisa, Lulli, Valentina, Caprara, Valentina, Rosanò, Laura, Goeman, Frauke, Carosi, Mariantonia, Di Giuliani, Marta, Vari, Giulia, Silvani, Antonio, Pollo, Bianca, Garufi, Carlo, Ramponi, Sara, Simonetti, Giorgia, Ciusani, Emilio, Mandoj, Chiara, Scalera, Stefano, Villani, Veronica, Po, Agnese, Ferretti, Elisabetta, Regazzo, Giulia, and Rizzo, Maria Giulia

Abstract

Additional file 1.

Published
2023
Full Text
View/download PDF

20. A Prospective Study Evaluating Health-Related Quality of Life Following a Multimodal Treatment for Colorectal Cancer

Author

Perrone, Maria, primary, Garufi, Carlo, additional, Cosimelli, Maurizio, additional, Graziano, Franco, additional, Falcicchio, Chiara, additional, Bonucci, Alessandro, additional, Fotia, Luana, additional, Giannarelli, Diana, additional, Giacomelli, Luca, additional, Ciliberto, Gennaro, additional, and Pugliese, Patrizia, additional

Published
2022
Full Text
View/download PDF

22. Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer : results from the International EORTC 05011 Trial

Author

Innominato, Pasquale F., Karaboué, Abdoulaye, Focan, Christian, Chollet, Philippe, Giacchetti, Sylvie, Bouchahda, Mohamed, Ulusakarya, Ayhan, Torsello, Angela, Adam, René, Lévi, Francis A., and Garufi, Carlo

Subjects
RM, RC
Abstract

The triplet combination of irinotecan, oxaliplatin and fluorouracil is an active frontline regimen in metastatic colorectal cancer, but scarce data exist on its use as salvage treatment. We aimed at assessing its safety and efficacy profiles with its circadian‐based administration (chronoIFLO5) as either first‐ or second‐line treatment, within the time‐finding EORTC 05011 trial. Five‐day chronoIFLO5 was administered every 3 weeks in patients with PS 0, 1 or 2. It consisted of chronomodulated irinotecan (180 mg/sqm), oxaliplatin (80 mg/sqm) and fluorouracil‐leucovorin (2800 and 1200 mg/sqm, respectively). For our study, toxicity and antitumour activity were evaluated separately in first‐ and second‐line settings. Primary endpoints included Grade 3‐4 toxicity rates, best objective response rate (ORR), progression‐free survival (PFS) and overall survival (OS). One‐hundred forty‐nine and 44 patients were treated in first‐line and second‐line settings, respectively, with a total of 1138 cycles with median relative dose intensities of about 90%. Demographics were comparable in the two groups. Thirty‐six (24.7%) and 10 (22.2%) patients experienced at least one episode of severe toxicity in first line and second line, respectively. Frontline chronoIFLO5 yielded an ORR of 62.3% [95% CI: 54.2‐70.4] and resulted in median PFS and OS of 8.7 months [7.5‐9.9] and 19.9 months [15.4‐24.5]. Corresponding figures in second line were 37.5% [22.5‐52.5], 6.7 months [4.8‐8.9] and 16.3 months [11.8‐20.8]. International and prospective evaluation revealed the favourable safety and efficacy profiles of chronoIFLO5, both as frontline and as salvage treatment against metastatic colorectal cancer. In particular, encouraging activity in second line was observed, with limited haematological toxicity.

Published
2021

23. Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer

Author

Zaniboni, Alberto, primary, Barone, Carlo Antonio, additional, Banzi, Maria Chiara, additional, Bergamo, Francesca, additional, Blasi, Livio, additional, Bordonaro, Roberto, additional, Bartolomeo, Maria Di, additional, Costanzo, Francesco Di, additional, Frassineti, Giovanni Luca, additional, Garufi, Carlo, additional, Giuliani, Francesco, additional, Latiano, Tiziana Pia, additional, Martinelli, Erika, additional, Personeni, Nicola, additional, Racca, Patrizia, additional, Tamburini, Emiliano, additional, Tonini, Giuseppe, additional, Besse, Marie Georges, additional, Spione, Mario, additional, and Falcone, Alfredo, additional

Published
2021
Full Text
View/download PDF

25. Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer : randomized multicenter

Author

Innominato, Pasquale F., Ballesta, Annabelle, Huang, Qi, Focan, Christian, Chollet, Philippe, Karaboué, Abdoulaye, Giacchetti, Sylvie, Bouchahda, Mohamed, Adam, René, Garufi, Carlo, and Lévi, Francis A.

Subjects
RC0254, QP
Abstract

The least toxic time (LTT) of irinotecan varied by up to 8 hours according to sex and genetic background in mice. The translational relevance was investigated within a randomized trial dataset, where no LTT stood out significantly in the whole population.\ud \ud 130 male and 63 female eligible patients with metastatic colorectal cancer were randomized to receive chronomodulated Irinotecan with peak delivery rate at 1 of 6 clock hours staggered by 4 hours on day 1, then fixed‐time chronomodulated Fluorouracil‐Leucovorin‐Oxaliplatin for 4 days, q3 weeks. The sex‐specific circadian characteristics of grade (G) 3‐4 toxicities were mapped with cosinor and time*sex interactions confirmed with Fisher's exact test.\ud \ud Baseline characteristics of male or female patients were similar in the six treatment groups. Main grade 3‐4 toxicities over six courses were diarrhea (males vs females, 39.2%; vs 46.0%), neutropenia (15.6% vs 15.0%), fatigue (11.5% vs 15.9%), and anorexia (10.0% vs 7.8%). They were reduced following irinotecan peak delivery in the morning for males, but in the afternoon for females, with statistically significant rhythms (P < .05 from cosinor) and sex*timing interactions (Fisher's exact test, diarrhea, P = .023; neutropenia, P = .015; fatigue, P = .062; anorexia, P = .032). Irinotecan timing was most critical for females, with grades 3‐4 ranging from 55.2% of the patients (morning) to 29.4% (afternoon) for diarrhea, and from 25.9% (morning) to 0% (afternoon) for neutropenia.\ud \ud The study results support irinotecan administration in the morning for males and in the afternoon for females, in order to minimize adverse events without impairing efficacy.

Published
2020

26. Additional file 1 of Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Author

Bon, Giulia, Pizzuti, Laura, Laquintana, Valentina, Loria, Rossella, Porru, Manuela, Marchiò, Caterina, Krasniqi, Eriseld, Barba, Maddalena, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, Verde, Nicla La, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Barchiesi, Giacomo, Mazzotta, Marco, Marinelli, Daniele, Tomao, Silverio, Marchetti, Paolo, Valerio, Maria Rosaria, Mirabelli, Rosanna, Russo, Antonio, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Giotta, Francesco, Garufi, Carlo, Cazzaniga, Marina, Medico, Pietro Del, Roselli, Mario, Sanguineti, Giuseppe, Sperduti, Isabella, Sapino, Anna, Maria, Ruggero De, Leonetti, Carlo, Leo, Angelo Di, Ciliberto, Gennaro, Falcioni, Rita, and Vici, Patrizia

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2020
Full Text
View/download PDF

27. Additional file 2 of Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Author

Bon, Giulia, Pizzuti, Laura, Laquintana, Valentina, Loria, Rossella, Porru, Manuela, Marchiò, Caterina, Krasniqi, Eriseld, Barba, Maddalena, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, Verde, Nicla La, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Barchiesi, Giacomo, Mazzotta, Marco, Marinelli, Daniele, Tomao, Silverio, Marchetti, Paolo, Valerio, Maria Rosaria, Mirabelli, Rosanna, Russo, Antonio, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Giotta, Francesco, Garufi, Carlo, Cazzaniga, Marina, Medico, Pietro Del, Roselli, Mario, Sanguineti, Giuseppe, Sperduti, Isabella, Sapino, Anna, Maria, Ruggero De, Leonetti, Carlo, Leo, Angelo Di, Ciliberto, Gennaro, Falcioni, Rita, and Vici, Patrizia

Subjects
Data_FILES
Abstract

Additional file 2.

Published
2020
Full Text
View/download PDF

28. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

Author

Krasniqi, E, Pizzuti, L, Barchiesi, G, Sergi, D, Carpano, S, Botti, C, Kayal, R, Sanguineti, G, Marchetti, P, Botticelli, A, Marinelli, D, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Tomao, S, Tonini, G, Santini, D, Michelotti, A, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Cazzaniga, M, Moscetti, L, Fabbri, A, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Garufi, C, Di Stefano, P, Mirabelli, R, Veltri, E, Paris, I, Giotta, F, Lorusso, V, Landucci, E, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Valerio, M, Berardi, R, Pistelli, M, Cannita, K, Zamagni, C, Garrone, O, Baldini, E, Livi, L, Meattini, I, Del Medico, P, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Villa, A, Sperduti, I, Mazzotta, M, Barba, M, Giordano, A, Vici, P, Krasniqi, Eriseld, Pizzuti, Laura, Barchiesi, Giacomo, Sergi, Domenico, Carpano, Silvia, Botti, Claudio, Kayal, Ramy, Sanguineti, Giuseppe, Marchetti, Paolo, Botticelli, Andrea, Marinelli, Daniele, Gamucci, Teresa, Natoli, Clara, Grassadonia, Antonino, Tinari, Nicola, Tomao, Silverio, Tonini, Giuseppe, Santini, Daniele, Michelotti, Aandrea, Mentuccia, Lucia, Vaccaro, Aangela, Magnolfi, Emanuela, Gelibter, Alain, Magri, Valentina, Cortesi, Enrico, D'Onofrio, Loretta, Cassano, Alessandra, Cazzaniga, Marina, Moscetti, Luca, Fabbri, Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Bria, Emilio, La Verde, Nicla, Garufi, Carlo, Di Stefano, Pia, Mirabelli, Rossana, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Lorusso, Vito, Landucci, Elisa, Ficorella, Corrado, Roselli, Mario, Adamo, Vincenzo, Ricciardi, Giuseppina, Russo, Antonio, Valerio, Maria Rosaria, Berardi, Rossana, Pistelli, Mirco, Cannita, Katia, Zamagni, Claudio, Garrone, Ornella, Baldini, Editta, Livi, Lorenzo, Meattini, Icro, Del Medico, Pietro, Generali, Daniele, De Maria, Ruggero, Risi, Emanuela, Ciliberto, Gennaro, Villa, Alice, Sperduti, Isabella, Mazzotta, Marco, Barba, Maddalena, Giordano, Antonio, Vici, Patrizia, Krasniqi, E, Pizzuti, L, Barchiesi, G, Sergi, D, Carpano, S, Botti, C, Kayal, R, Sanguineti, G, Marchetti, P, Botticelli, A, Marinelli, D, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Tomao, S, Tonini, G, Santini, D, Michelotti, A, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Cazzaniga, M, Moscetti, L, Fabbri, A, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Garufi, C, Di Stefano, P, Mirabelli, R, Veltri, E, Paris, I, Giotta, F, Lorusso, V, Landucci, E, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Valerio, M, Berardi, R, Pistelli, M, Cannita, K, Zamagni, C, Garrone, O, Baldini, E, Livi, L, Meattini, I, Del Medico, P, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Villa, A, Sperduti, I, Mazzotta, M, Barba, M, Giordano, A, Vici, P, Krasniqi, Eriseld, Pizzuti, Laura, Barchiesi, Giacomo, Sergi, Domenico, Carpano, Silvia, Botti, Claudio, Kayal, Ramy, Sanguineti, Giuseppe, Marchetti, Paolo, Botticelli, Andrea, Marinelli, Daniele, Gamucci, Teresa, Natoli, Clara, Grassadonia, Antonino, Tinari, Nicola, Tomao, Silverio, Tonini, Giuseppe, Santini, Daniele, Michelotti, Aandrea, Mentuccia, Lucia, Vaccaro, Aangela, Magnolfi, Emanuela, Gelibter, Alain, Magri, Valentina, Cortesi, Enrico, D'Onofrio, Loretta, Cassano, Alessandra, Cazzaniga, Marina, Moscetti, Luca, Fabbri, Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Bria, Emilio, La Verde, Nicla, Garufi, Carlo, Di Stefano, Pia, Mirabelli, Rossana, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Lorusso, Vito, Landucci, Elisa, Ficorella, Corrado, Roselli, Mario, Adamo, Vincenzo, Ricciardi, Giuseppina, Russo, Antonio, Valerio, Maria Rosaria, Berardi, Rossana, Pistelli, Mirco, Cannita, Katia, Zamagni, Claudio, Garrone, Ornella, Baldini, Editta, Livi, Lorenzo, Meattini, Icro, Del Medico, Pietro, Generali, Daniele, De Maria, Ruggero, Risi, Emanuela, Ciliberto, Gennaro, Villa, Alice, Sperduti, Isabella, Mazzotta, Marco, Barba, Maddalena, Giordano, Antonio, and Vici, Patrizia

Abstract

Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p =.15), while BMI ≥ 30 was associated with worse OS (p =.003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p =.001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p =.03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.

Published
2020

30. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade. The SePHER Study.

Author

Bon, Giulia, primary, Pizzuti, Laura, additional, Laquintana, Valentina, additional, Loria, Rossella, additional, Porru, Manuela, additional, Marchiò, Caterina, additional, Krasniqi, Erisled, additional, Barba, Maddalena, additional, Maugeri-Saccà, Marcello, additional, Gamucci, Teresa, additional, Berardi, Rossana, additional, Livi, Lorenzo, additional, Ficorella, Corrado, additional, Natoli, Clara, additional, Cortesi, Enrico, additional, Generali, Daniele, additional, Verde, Nicla La, additional, Cassano, Alessandra, additional, Bria, Emilio, additional, Moscetti, Luca, additional, Michelotti, Andrea, additional, Adamo, Vincenzo, additional, Zamagni, Claudio, additional, Tonini, Giuseppe, additional, Barchiesi, Giacomo, additional, Mazzotta, Marco, additional, Marinelli, Daniele, additional, Tomao, Silverio, additional, Marchetti, Paolo, additional, Valerio, Maria Rosaria, additional, Mirabelli, Rosanna, additional, Russo, Antonio, additional, Fabbri, Maria Agnese, additional, D'Ostilio, Nicola, additional, Veltri, Enzo, additional, Corsi, Domenico, additional, Garrone, Ornella, additional, Paris, Ida, additional, Sarobba, Giuseppina, additional, Giotta, Francesco, additional, Garufi, Carlo, additional, Cazzaniga, Marina, additional, Medico, Pietro Del, additional, Roselli, Mario, additional, Sanguineti, Giuseppe, additional, Sperduti, Isabella, additional, Sapino, Anna, additional, De Maria, Ruggero, additional, Leonetti, Carlo, additional, Leo, Angelo Di, additional, Ciliberto, Gennaro, additional, Falcioni, Rita, additional, and Vici, Patrizia, additional

Published
2020
Full Text
View/download PDF

31. Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial

Author

Innominato, Pasquale F., primary, Karaboué, Abdoulaye, additional, Focan, Christian, additional, Chollet, Philippe, additional, Giacchetti, Sylvie, additional, Bouchahda, Mohamed, additional, Ulusakarya, Ayhan, additional, Torsello, Angela, additional, Adam, René, additional, Lévi, Francis A., additional, and Garufi, Carlo, additional

Published
2020
Full Text
View/download PDF

36. HER2 Nuclear Translocation and Decreased T-DM1 Efficacy in HER2 Positive Advanced Breast Cancer Treated with Dual HER2 Blockade. The SePHER Study.

Author

Bon, Giulia, primary, Pizzuti, Laura, additional, Laquintana, Valentina, additional, Loria, Rossella, additional, Porru, Manuela, additional, Marchiò, Caterina, additional, Krasniqi, Erisled, additional, Barba, Maddalena, additional, Maugeri-Saccà, Marcello, additional, Gamucci, Teresa, additional, Berardi, Rossana, additional, Livi, Lorenzo, additional, Ficorella, Corrado, additional, Natoli, Clara, additional, Cortesi, Enrico, additional, Generali, Daniele, additional, Verde, Nicla La, additional, Cassano, Alessandra, additional, Bria, Emilio, additional, Moscetti, Luca, additional, Michelotti, Andrea, additional, Adamo, Vincenzo, additional, Zamagni, Claudio, additional, Tonini, Giuseppe, additional, Barchiesi, Giacomo, additional, Mazzotta, Marco, additional, Marinelli, Daniele, additional, Tomao, Silverio, additional, Marchetti, Paolo, additional, Valerio, Maria Rosaria, additional, Mirabelli, Rosanna, additional, Russo, Antonio, additional, Fabbri, Maria Agnese, additional, D'Ostilio, Nicola, additional, Veltri, Enzo, additional, Corsi, Domenico, additional, Garrone, Ornella, additional, Paris, Ida, additional, Sarobba, Giuseppina, additional, Giotta, Francesco, additional, Garufi, Carlo, additional, Cazzaniga, Marina, additional, Medico, Pietro Del, additional, Roselli, Mario, additional, Sanguineti, Giuseppe, additional, Sperduti, Isabella, additional, Sapino, Anna, additional, De Maria, Ruggero, additional, Leonetti, Carlo, additional, Leo, Angelo Di, additional, Ciliberto, Gennaro, additional, Falcioni, Rita, additional, and Vici, Patrizia, additional

Published
2020
Full Text
View/download PDF

38. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence

Author

Krasniqi, Eriseld, primary, Pizzuti, Laura, additional, Barchiesi, Giacomo, additional, Sergi, Domenico, additional, Carpano, Silvia, additional, Botti, Claudio, additional, Kayal, Ramy, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Botticelli, Andrea, additional, Marinelli, Daniele, additional, Gamucci, Teresa, additional, Natoli, Clara, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Tomao, Silverio, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Michelotti, Aandrea, additional, Mentuccia, Lucia, additional, Vaccaro, Aangela, additional, Magnolfi, Emanuela, additional, Gelibter, Alain, additional, Magri, Valentina, additional, Cortesi, Enrico, additional, D’Onofrio, Loretta, additional, Cassano, Alessandra, additional, Cazzaniga, Marina, additional, Moscetti, Luca, additional, Fabbri, Agnese, additional, Scinto, Angelo Fedele, additional, Corsi, Domenico, additional, Carbognin, Luisa, additional, Bria, Emilio, additional, La Verde, Nicla, additional, Garufi, Carlo, additional, Di Stefano, Pia, additional, Mirabelli, Rossana, additional, Veltri, Enzo, additional, Paris, Ida, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Landucci, Elisa, additional, Ficorella, Corrado, additional, Roselli, Mario, additional, Adamo, Vincenzo, additional, Ricciardi, Giuseppina, additional, Russo, Antonio, additional, Valerio, Maria Rosaria, additional, Berardi, Rossana, additional, Pistelli, Mirco, additional, Cannita, Katia, additional, Zamagni, Claudio, additional, Garrone, Ornella, additional, Baldini, Editta, additional, Livi, Lorenzo, additional, Meattini, Icro, additional, Del Medico, Pietro, additional, Generali, Daniele, additional, De Maria, Ruggero, additional, Risi, Emanuela, additional, Ciliberto, Gennaro, additional, Villa, Alice, additional, Sperduti, Isabella, additional, Mazzotta, Marco, additional, Barba, Maddalena, additional, Giordano, Antonio, additional, and Vici, Patrizia, additional

Published
2020
Full Text
View/download PDF

39. Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group

Author

Giacchetti, Sylvie, Bjarnason, Georg, Garufi, Carlo, Genet, Dominique, Iacobelli, Stefano, Tampellini, Marco, Smaaland, Rune, Focan, Christian, Coudert, Bruno, Humblet, Yves, Canon, Jean Luc, Adenis, Antoine, Lo Re, Giovanni, Carvalho, Carlos, Schueller, Johannes, Anciaux, Nicole, Lentz, Marie-Ange, Baron, Benoît, Gorlia, Thierry, and Lévi, Francis

Published
2006
Full Text
View/download PDF

41. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

Author

Gamucci, Teresa, Pizzuti, Laura, Natoli, Clara, Mentuccia, Lucia, Sperduti, Isabella, Barba, Maddalena, Sergi, Domenico, Iezzi, Laura, Maugeri-Saccà, Marcello, Vaccaro, Angela, Magnolfi, Emanuela, Gelibter, Alain, Barchiesi, Giacomo, Magri, Valentina, D’Onofrio, Loretta, Cassano, Alessandra, Rossi, Ernesto, Botticelli, Andrea, Moscetti, Luca, Omarini, Claudia, Fabbri, Maria Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Mazzotta, Marco, Bria, Emilio, Foglietta, Jennifer, Samaritani, Riccardo, Garufi, Carlo, Mariani, Luciano, Barni, Sandro, Mirabelli, Rosanna, Sarmiento, Roberta, Graziano, Vincenzo, Santini, Daniele, Marchetti, Paolo, Tonini, Giuseppe, Di Lauro, Luigi, Sanguineti, Giuseppe, Paoletti, Giancarlo, Tomao, Silverio, De Maria Marchiano, Ruggero, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Latorre, Agnese, Giordano, Antonio, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Corsi, Domenico Cristiano, Bria, Emilio (ORCID:0000-0002-2333-704X), De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Gamucci, Teresa, Pizzuti, Laura, Natoli, Clara, Mentuccia, Lucia, Sperduti, Isabella, Barba, Maddalena, Sergi, Domenico, Iezzi, Laura, Maugeri-Saccà, Marcello, Vaccaro, Angela, Magnolfi, Emanuela, Gelibter, Alain, Barchiesi, Giacomo, Magri, Valentina, D’Onofrio, Loretta, Cassano, Alessandra, Rossi, Ernesto, Botticelli, Andrea, Moscetti, Luca, Omarini, Claudia, Fabbri, Maria Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Mazzotta, Marco, Bria, Emilio, Foglietta, Jennifer, Samaritani, Riccardo, Garufi, Carlo, Mariani, Luciano, Barni, Sandro, Mirabelli, Rosanna, Sarmiento, Roberta, Graziano, Vincenzo, Santini, Daniele, Marchetti, Paolo, Tonini, Giuseppe, Di Lauro, Luigi, Sanguineti, Giuseppe, Paoletti, Giancarlo, Tomao, Silverio, De Maria Marchiano, Ruggero, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Latorre, Agnese, Giordano, Antonio, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Corsi, Domenico Cristiano, Bria, Emilio (ORCID:0000-0002-2333-704X), and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)

Abstract

We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy of first-line treatment with pertuzumab/trastuzumab/taxane in real-world setting. Survival data were analyzed by Kaplan Meier curves and log rank test. Median follow-up, length of pertuzumab/trastuzumab/taxane treatment and of pertuzumab, trastuzumab maintenance were 21, 4 and 15 months, respectively. The response rate was 77.3%, and the clinical benefit rate 93.6%. Median progression-free survival (mPFS) was 21 months, and median overall survival (mOS) was not reached. When comparing patients by trastuzumab-pretreatment, similar PFS were observed, although a longer OS was reached in trastuzumab-naïve patients (p = 0.02). Brain metastases at baseline and their development in course of therapy were associated with significantly shorter PFS (p = 0.0006) and shorter OS, although at a not fully statistically relevant extent (p = 0.06). The addition of maintenance endocrine therapy (ET) to pertuzumab/trastuzumab maintenance was associated with longer PFS (p = 0.0001), although no significant differences were detected in OS (p = 0.31). Results were confirmed by propensity score analysis (p = 0.003 and p = 0.46, respectively). In multivariate models, longer PFS was related to lower Performance Status (PS) (p = 0.07), metastatic stage at diagnosis (p = 0.006) and single metastatic site (p < 0.0001). An OS advantage was observed with lower PS (p < 0.0001), single metastatic site (p = 0.004), no prior exposure to trastuzumab (p = 0.004) and response to pertuzumab-based treatment (p = 0.003). Our results confirm that trastuzumab/pertuzumab/taxane is the standard of care as first-line treatment of patients with HER2-positive ABC even in the real-world setting. Moreover, the double-maintenance therapy (HER2 block and ET) is strongly recommended when feasible.

Published
2019

46. Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or secondline treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial.

Author

Innominato, Pasquale F., Karaboué, Abdoulaye, Focan, Christian, Chollet, Philippe, Giacchetti, Sylvie, Bouchahda, Mohamed, Ulusakarya, Ayhan, Torsello, Angela, Adam, René, Lévi, Francis A., and Garufi, Carlo

Subjects
COLORECTAL cancer, IRINOTECAN, METASTASIS, DRUG efficacy, OXALIPLATIN
Abstract

The triplet combination of irinotecan, oxaliplatin and fluorouracil is an active frontline regimen in metastatic colorectal cancer, but scarce data exist on its use as salvage treatment. We aimed at assessing its safety and efficacy profiles with its circadianbased administration (chronoIFLO5) as either first- or second-line treatment, within the time-finding EORTC 05011 trial. Five-day chronoIFLO5 was administered every 3 weeks in patients with PS 0, 1 or 2. It consisted of chronomodulated irinotecan (180 mg/sqm), oxaliplatin (80 mg/sqm) and fluorouracil-leucovorin (2800 and 1200 mg/sqm, respectively). For our study, toxicity and antitumour activity were evaluated separately in first- and second-line settings. Primary endpoints included Grade 3-4 toxicity rates, best objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). One-hundred forty-nine and 44 patients were treated in first-line and second-line settings, respectively, with a total of 1138 cycles with median relative dose intensities of about 90%. Demographics were comparable in the two groups. Thirty-six (24.7%) and 10 (22.2%) patients experienced at least one episode of severe toxicity in first line and second line, respectively. Frontline chronoIFLO5 yielded an ORR of 62.3% [95% CI: 54.2-70.4] and resulted in median PFS and OS of 8.7 months [7.5-9.9] and 19.9 months [15.4-24.5]. Corresponding figures in second line were 37.5% [22.5-52.5], 6.7 months [4.8-8.9] and 16.3 months [11.8-20.8]. International and prospective evaluation revealed the favourable safety and efficacy profiles of chronoIFLO5, both as frontline and as salvage treatment against metastatic colorectal cancer. In particular, encouraging activity in second line was observed, with limited haematological toxicity [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting

Author

Pizzuti, Laura, primary, Krasniqi, Eriseld, additional, Barchiesi, Giacomo, additional, Della Giulia, Marina, additional, Izzo, Fiorentino, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Mazzotta, Marco, additional, Giusti, Raffaele, additional, Botticelli, Andrea, additional, Gamucci, Teresa, additional, Natoli, Clara, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Iezzi, Laura, additional, Tomao, Silverio, additional, Tomao, Federica, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Astone, Antonio, additional, Michelotti, Andrea, additional, De Angelis, Claudia, additional, Mentuccia, Lucia, additional, Vaccaro, Angela, additional, Magnolfi, Emanuela, additional, Gelibter, Alain, additional, Magri, Valentina, additional, Cortesi, Enrico, additional, D'Onofrio, Loretta, additional, Cassano, Alessandra, additional, Rossi, Ernesto, additional, Cazzaniga, Marina, additional, Moscetti, Luca, additional, Omarini, Claudia, additional, Piacentini, Federico, additional, Fabbri, Maria A., additional, Scinto, Angelo F., additional, Corsi, Domenico, additional, Carbognin, Luisa, additional, Bria, Emilio, additional, La Verde, Nicla, additional, Samaritani, Riccardo, additional, Garufi, Carlo, additional, Barni, Sandro, additional, Mirabelli, Rosanna, additional, Sarmiento, Roberta, additional, Veltri, Enzo M., additional, D'Auria, Giuliana, additional, Paris, Ida, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Cardillo, Franca, additional, Landucci, Elisabetta, additional, Mauri, Maria, additional, Ficorella, Corrado, additional, Roselli, Mario, additional, Adamo, Vincenzo, additional, Ricciardi, Giuseppina R.R., additional, Russo, Antonio, additional, Berardi, Rossana, additional, Pistelli, Mirco, additional, Fiorio, Elena, additional, Cannita, Katia, additional, Sini, Valentina, additional, D'Ostilio, Nicola, additional, Foglietta, Jennifer, additional, Greco, Filippo, additional, Zamagni, Claudio, additional, Garrone, Ornella, additional, Di Cocco, Barbara, additional, Baldini, Editta, additional, Livi, Lorenzo, additional, Desideri, Isacco, additional, Meattini, Icro, additional, Sarobba, Giuseppina, additional, Del Medico, Pietro, additional, De Tursi, Michele, additional, Generali, Daniele, additional, De Maria, Ruggero, additional, Risi, Emanuela, additional, Ciliberto, Gennaro, additional, Sperduti, Isabella, additional, Villa, Alice, additional, Barba, Maddalena, additional, Di Leo, Angelo, additional, and Vici, Patrizia, additional

Published
2019
Full Text
View/download PDF

48. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Author

Cortellini, Alessio, primary, Buti, Sebastiano, additional, Santini, Daniele, additional, Perrone, Fabiana, additional, Giusti, Raffaele, additional, Tiseo, Marcello, additional, Bersanelli, Melissa, additional, Michiara, Maria, additional, Grassadonia, Antonino, additional, Brocco, Davide, additional, Tinari, Nicola, additional, De Tursi, Michele, additional, Zoratto, Federica, additional, Veltri, Enzo, additional, Marconcini, Riccardo, additional, Malorgio, Francesco, additional, Garufi, Carlo, additional, Russano, Marco, additional, Anesi, Cecilia, additional, Zeppola, Tea, additional, Filetti, Marco, additional, Marchetti, Paolo, additional, Botticelli, Andrea, additional, Antonini Cappellini, Gian Carlo, additional, De Galitiis, Federica, additional, Vitale, Maria Giuseppa, additional, Sabbatini, Roberto, additional, Bracarda, Sergio, additional, Berardi, Rossana, additional, Rinaldi, Silvia, additional, Tudini, Marianna, additional, Silva, Rosa Rita, additional, Pireddu, Annagrazia, additional, Atzori, Francesco, additional, Chiari, Rita, additional, Ricciuti, Biagio, additional, Iacono, Daniela, additional, Migliorino, Maria Rita, additional, Rossi, Antonio, additional, Porzio, Giampiero, additional, Cannita, Katia, additional, Ciciarelli, Valeria, additional, Fargnoli, Maria Concetta, additional, Ascierto, Paolo Antonio, additional, and Ficorella, Corrado, additional

Published
2019
Full Text
View/download PDF

49. Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.

Author

Troiani, Teresa, primary, Martinelli, Erika, additional, Ciardiello, Davide, additional, Zanaletti, Nicoletta, additional, Cardone, Claudia, additional, Borrelli, Carola, additional, Avallone, Antonio, additional, Falcone, Alfredo, additional, Maiello, Evaristo, additional, Bordonaro, Roberto, additional, Santini, Daniele, additional, Garufi, Carlo, additional, De Braud, Filippo G., additional, Pinto, Carmine, additional, Gridelli, Cesare, additional, and Ciardiello, Fortunato, additional

Published
2019
Full Text
View/download PDF

50. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

Author

Gamucci, Teresa, primary, Pizzuti, Laura, additional, Natoli, Clara, additional, Mentuccia, Lucia, additional, Sperduti, Isabella, additional, Barba, Maddalena, additional, Sergi, Domenico, additional, Iezzi, Laura, additional, Maugeri-Saccà, Marcello, additional, Vaccaro, Angela, additional, Magnolfi, Emanuela, additional, Gelibter, Alain, additional, Barchiesi, Giacomo, additional, Magri, Valentina, additional, D’Onofrio, Loretta, additional, Cassano, Alessandra, additional, Rossi, Ernesto, additional, Botticelli, Andrea, additional, Moscetti, Luca, additional, Omarini, Claudia, additional, Fabbri, Maria Agnese, additional, Scinto, Angelo Fedele, additional, Corsi, Domenico, additional, Carbognin, Luisa, additional, Mazzotta, Marco, additional, Bria, Emilio, additional, Foglietta, Jennifer, additional, Samaritani, Riccardo, additional, Garufi, Carlo, additional, Mariani, Luciano, additional, Barni, Sandro, additional, Mirabelli, Rosanna, additional, Sarmiento, Roberta, additional, Graziano, Vincenzo, additional, Santini, Daniele, additional, Marchetti, Paolo, additional, Tonini, Giuseppe, additional, Di Lauro, Luigi, additional, Sanguineti, Giuseppe, additional, Paoletti, Giancarlo, additional, Tomao, Silverio, additional, De Maria, Ruggero, additional, Veltri, Enzo, additional, Paris, Ida, additional, Giotta, Francesco, additional, Latorre, Agnese, additional, Giordano, Antonio, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results